Retrospective Observational Study to Compare Cystic Fibrosis Patients in Two Decades Before and After 2000
Completed
- Conditions
- Cystic Fibrosis
- Registration Number
- NCT01651455
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Brief Summary
The purpose of this study is to describe two cohorts of cystic fibrosis patients treated in 2 different decades in terms of FEV1 (Forced Expiratory Volume in one second) maintenance.
- Detailed Description
The purpose of this study is to describe two cohorts of cystic fibrosis patients treated in terms of FEV1 maintenance from the age of 10 to 15 before and after 2000.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 92
Inclusion Criteria
- Patients with Cystic Fibrosis diagnosed with neo-natal screening
- Patients born between 01/01/1979 and 12/31/1984 (Cohort 1)and patients born between 01/01/1991 and 12/31/1996 (Cohort 2)
- Patients with at least 2 FEV1 yearly measurements from the age of 10 to 15
Exclusion Criteria
- Patients with malignant tumor
- Patients with meconium ileus
- Patients with transplantation (pneumectomy or lobectomy)
- Patients involved in any other clinical trial
- Patients moved to another Clinical Center
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To describe the difference in terms of FEV1 decline between two cohorts of cystic fibrosis patients 5 years
- Secondary Outcome Measures
Name Time Method To evaluate the number of patients with Pseudomonas Aeruginosa infection during observational period 5 years To identify clinical parameters or treatments correlated to FEV1 maintenance in two cohorts of cystic fibrosis patients 5 years To describe length of time without Pseudomonas A. infection in non-colonized patients during observational period. 5 years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms influence FEV1 maintenance in cystic fibrosis patients before and after 2000?
How does the standard-of-care treatment for cystic fibrosis compare in effectiveness between the two decades studied in NCT01651455?
Are there specific biomarkers that correlate with improved lung function outcomes in cystic fibrosis patients treated in the post-2000 era?
What adverse events are associated with cystic fibrosis therapies in the pre-2000 and post-2000 cohorts of NCT01651455?
How do combination therapies involving CFTR modulators impact FEV1 maintenance compared to traditional cystic fibrosis treatments in the context of NCT01651455?
Trial Locations
- Locations (1)
U.O. Azienda Ospedaliera
🇮🇹Verona, Veneto, Italy
U.O. Azienda Ospedaliera🇮🇹Verona, Veneto, Italy